MorphoSys AG: MorphoSys Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022

Preliminary Q2 2022 Monjuvi U.S. net product sales of US$ 23.3 million (€ 21.7 million)Update of financial guidance range for 2022 Monjuvi U.S. net product sales (now US$ 90 to US$ 110 million)Update of

Related Keywords

Germany ,Boston ,Massachusetts ,United States ,Canada ,United Kingdom ,Planegg ,Bayern ,Kaitlyn Nealy ,Thomas Biegi ,Julia Neugebauer ,Jean Paul Kress ,Myles Clouston ,Linkedin ,Xencor Inc ,Twitter ,Drug Administration ,Us Communications ,Exchange Commission ,Human Immunology Biosciences Inc ,Human Immunology Biosciences ,Product Sales ,Chief Executive Officer ,Gross Margin ,Antibody Dependent Cell Mediated Cytotoxicity ,Antibody Dependent Cellular Phagocytosis ,Morphosy Annual Report ,Morphosys ,Reports ,Reliminary ,022 ,Monjuvi ,Sales ,Updates ,Financial ,Guidance ,